Genomic instability is one mechanism proposed to play a role in the disease progression of chronic myeloid leukemia (CML). Microsatellite regions in the type II transforming growth factor-␤ receptor (TGF-␤ RII) gene appear to be targets for mutation in some cancers displaying microsatellite instability (replication error phenotype, RER 
Introduction
Chronic myelogenous leukemia (CML) is a disorder in which the normal regulatory growth controls of multipotent hematopoietic precursor cells are progressively lost. An initial chronic phase is characterised by an increase in the number of myeloid cells in the peripheral blood, with no apparent disruption of terminal differentiation. A block in terminal differentiation is correlated with transformation from the indolent chronic phase to an aggressive therapy-resistant acute phase (reviewed in Ref. 1) .
CML is associated with a specific karyotypic abnormality, the Philadelphia chromosome, where sequences from the ABL gene on chromosome 9 become juxtaposed with BCR sequences on chromosome 22. The fusion product, Bcr-Abl, has constitutive tyrosine kinase activity and is strongly implicated in the initiation of CML (reviewed in Ref. 2) .
Targets for Bcr-Abl phosphorylation include intracellular signalling molecules of the Ras and the phosphatidyl inositol-3-kinase (PI3K) pathways. Autophosphorylation on a tyrosine residue in Bcr allows binding of the adaptor protein Grb2.
by Ras, activated downstream of Grb2. Another adaptor protein, p62
dok , constitutively phosphorylated in blast cells expressing Bcr-Abl, may also play a role in the activation of Ras. 4 ,5 p120 CBL , a phosphotyrosine substrate in mitogenic signalling pathways, is a consistent target for phosphorylation by Bcr-Abl, brought into a complex with Bcr-Abl by the adaptor protein CRKL. 6 CRKL may also play a role in the altered intracellular localisation of p130 CAS , which could contribute to the adhesion abnormalities associated with CML progenitor cells. 7 Additionally, the Bcr-Abl protein induces Bcl-2 expression, rendering the cells resistant to apoptosis. 8 This may explain the accumulation of mature myeloid cells in the peripheral blood of patients in chronic phase despite no change in the kinetics of proliferation or maturation of myeloid precursor cells.
Molecular events associated with evolution from the chronic phase of CML to blast crisis are poorly understood. While Bcr-Abl is linked to the initiation of CML, its role in progression is unclear. Although Bcr-Abl is sufficient to evoke an acute leukemia in animal models, 9 the presence of a prolonged initial phase in human CML suggests that secondary genetic events underly leukemic progression. Abnormal survival of cells that express Bcr-Abl may allow accumulation of further mutations. Certainly, acute leukemic transformation is associated with an increase in additional chromosomal abnormalities including trisomy 8, an extra Philadelphia chromosome and isochromosome 17 (reviewed in Ref. 10) . Point mutations in p53 and Ras (reviewed in Ref. 11 ) and aberrant expression of p185 HER2 12 have also been implicated in disease progression.
Microsatellite instability develops when proteins involved in mismatch repair are inactivated allowing multiple genetic errors to accumulate. Discovery of mismatch repair gene mutations in leukemias and lymphomas, and the susceptibility of mice bearing a targeted disruption in the MSH-2 gene to lymphoid tumors, suggest that genomic instability is important in hematological malignancies. [13] [14] [15] [16] Development of microsatellite instability has been implicated in the evolution of CML to blast crisis. 17 Mutations endowing the cell with a proliferative advantage may be selected for and clonal evolution of this cell may further progression towards the acute phase. Such a mechanism has been implicated in the progression of colorectal cancer. 18, 19 In colonic tumor cells with microsatellite instability, the type II transforming growth factor-␤ receptor (TGF-␤ RII) is often inactivated, suggesting that a proliferative advantage is given to cells that escape the negative regulation of TGF-␤. Two specific mutations within microsatellite regions of the TGF-␤ RII gene have been associated with the decreased or absent expression of the receptor; a 1-2 base deletion within a sequence of 10 adenine residues or a GT insertion in a six base pair GT repeat. The adenine deletion has also been found in RER + gastric cancer, 20 ampullary carcinomas 21 and gliomas. 22 TGF-␤ is a potent regulator of hematopoiesis, raising the possibility that inactivation of TGF-␤ RII as a result of microsatellite instability may be involved in leukemogenesis. TGF-␤ has a strong growth inhibitory effect on early hematopoietic progenitor cells, acting to increase the time these cells spend in G1. 23 A differentiative effect of TGF-␤ has been observed on later progenitor cells. 24 Loss of a functional TGF-␤ RII and consequent loss of the proliferative and differentiative control of TGF-␤ on hematopoietic progenitor cells may provide an explanation for the disruption of the balance between proliferation and differentiation that occurs as CML progresses. To investigate this possibility, studies were undertaken to determine whether inactivation of TGF-␤ RII by microsatellite alteration might be involved in the progression of CML.
Materials and methods

Cell lines
The cell lines HL-60, K562, KG-1, Jurkat, U937 and HCT116 were obtained from the American Type Culture Collection. HL-60, K562, KG-1, Jurkat and U937 were maintained in RPMI supplemented with 10% fetal calf serum, penicillin (50 U/ml), streptomycin (50 g/ml) and glutamine (2 mM). The M-07 cell line 25 was cultured in the same media, supplemented with recombinant human interleukin 3 (30 ng/ml). Cells were incubated at 37°C in 5% CO 2 in humidified air. HCT116 was maintained in DMEM, supplemented as above and incubated at 37°C in 10% CO 2 in humidified air.
Patient samples
Primary leukemic cells were obtained from the bone marrow or peripheral blood of patients with CML at presentation and during the course of the disease (Table 1) . Leukemic cells were isolated by red cell lysis of whole blood or separated into mononuclear and neutrophil components by centrifugation through Ficoll-Paque (Pharmacia, Uppsala, Sweden) followed by red cell lysis. Cells were isolated from peripheral blood from two normal donors (N1-2) by red cell lysis. Neutrophils were also isolated from normal donors (N3-6) and patients with polycythemia rubra vera (PRV1-3) or essential thrombocythemia (ET1-2). Morphological analysis of stained cell smears confirmed that preparations of neutrophils were Ͼ95% pure. DNA was extracted by concurrent cell lysis and proteinase K digestion followed by phenol/chloroform extraction. RNA was isolated either by acid guanidinium isothiocyanate extraction or using the TRIzol Reagent (Gibco BRL, Gaithersburg, MD, USA) and recommended protocol. Ethical approval for this work was obtained from the North Health Ethics Committee, New Zealand.
RNase protection analysis
The riboprobe used for analysis of TGF-␤ RII expression was derived from a PCR product including nucleotides 1095-1350 of the wild-type TGF-␤ RII cDNA (GenBank accession M85079) cloned into pGEM-4Z. The free probe yielded a 293 nucleotide (nt) band and a 256 nt fragment of this probe was protected by a TGF-␤ RII RNA transcript if present. As an internal control, a riboprobe containing ␤-actin sequence was included in the same reaction. This riboprobe was derived from a SalI-SmaI fragment of human ␤-actin. The length of the free ␤-actin probe was 132 nt and ␤-actin transcripts protected a 54 nt fragment.
In vitro-transcribed antisense riboprobes were labelled by incorporation of ␣ 32 P-CTP. RNase protection assays were performed by hybridisation of 7-15 g total RNA to the RNA probes (2 × 10 5 c.p.m.) overnight at 42°C. RNase digestion was performed with RNase T1 (1.75 g/ml) and RNase A (35 g/ml) at 30°C for 1 h. The reaction was terminated by addition of proteinase K (333 g/ml) and SDS (0.3%). RNA hybrids were purified by phenoform extraction and ethanol precipitation. Digestion products were separated on a 6% polyacrylamide gel containing 7 M urea. Autoradiographs were exposed overnight at −70°C.
Band intensity values were obtained using NIH Image 1.52. The ratio of mean intensity per pixel for each TGF-␤ RII band to that for each ␤-actin band was calculated to normalize for the amount of RNA present.
Sequencing
Regions of the TGF-␤ RII gene encompassing either the (A) 10 or the (GT) 3 microsatellite sequences were amplified by PCR from 125 ng cDNA template. Each reaction contained in 50 l: 1 × PCR buffer (10 mM Tris-Cl (pH 3.8), 50 mM KCl), PCR amplification products purified away from reaction components were directly sequenced by cycle sequencing using the fmol DNA Sequencing System (Promega, Madison, WI, USA) and a ␥ 33 P-ATP end-labelled sequence-specific oligonucleotide following the recommended protocol. Sequencing products were separated by electrophoresis in a 6% polyacrylamide gel containing 7 M urea and visualised by autoradiography.
Microsatellite analysis
A 73 bp fragment of the TGF-␤ RII gene encompassing the 10 adenine repeat was amplified by PCR from 100 ng genomic DNA using primers previously described. 19 The reaction contained in 50 l: 1 × PCR buffer (10 mM Tris-CI (pH 3.8), 50 mM KCI), 2.0 mM MgCI 2 , 2% DMSO, 200 M each dNTP, 2.5 U Taq polymerase, 20 pmol unlabelled forward primer, 25 pmol reverse primer and 1.5 pmol 33 P-end-labelled forward primer. Cycle parameters of 94°C for 1 min, 61°C for 1 min 30 s, 72°C for 1 min were used. Amplification products were separated by electrophoresis in a 6% polyacrylamide gel containing 7 M urea and visualised by autoradiography.
Each reaction series contained a control reaction that lacked template. Mutation (A 10 to A 9 ) positive and negative controls were obtained by amplification from genomic DNA isolated from the cell lines HCT116 and Jurkat, respectively. Control heterozygous populations were generated by mixing the above templates at different ratios.
Fidelity of the (GT) 3 microsatellite was assessed by sequencing of a PCR amplification product (spanning nt 1711-1972 of TGF-␤ RII cDNA) encompassing this region as described above.
Results
TGF-␤ type II receptor expression
Alterations of microsatellite regions have been reported to cause a decrease in, or complete loss of, TGF-␤ RII mRNA expression in colon carcinomas when compared with normal colonic epithelial cells. 18 Such a process, resulting in downregulation of TGF-␤ RII in hematopoietic cells could allow development of resistance to the TGF-␤ negative regulatory pathway.
Expression of the TGF-␤ RII transcript in human leukemia cell lines, representing a range of blood cell lineages, was assessed by RNase protection assay and compared with TGF-␤ RII expression in the colon carcinoma cell line, HCT116. A similar level of TGF-␤ RII mRNA expression was seen in RNA extracted from the hematopoietic cell lines Jurkat (T cell lymphoma), U-937 (histiocytic lymphoma) and M-07 (megakaryoblastic leukemia) and the colon carcinoma cell line HCT116 (Figure 1 ). Analysis of RNA from the cell lines K562 (derived from a patient with CML in blast crisis) and HL-60 (acute myeloid leukemia) demonstrated absence of the TGF-␤ RII transcript in these cell lines. To establish if gross structural alterations in the TGF-␤ RII gene in these cell lines Expression of TGF-␤ RII in human tumor cell lines. RNase protection analysis was performed on total RNA (15 g) from a range of human tumor cell lines. As a control, tRNA (15 g) was also used. The markers were pBR322 DNA digested with MspI. The size of the TGF-␤ RII free probe was 293 nt, and the presence of TGF-␤ RII transcripts was indicated by the protection of a 256 nt fragment. A 54 nt protected fragment of a ␤-actin probe included in each reaction is shown below as a control for loading.
had occurred, Southern analysis was performed. Restriction enzyme-digested genomic DNA separated by gel electrophoresis was probed with a random-primed cDNA probe which included the entire extracellular domain of TGF-␤ RII. Banding patterns were identical in K562, HL-60 and normal human genomic DNA suggesting that gross deletions of the TGF-␤ RII gene in K562 and HL-60 were not responsible for loss of TGF-␤ transcripts (data not shown).
To determine if expression of the TGF-␤ RII gene is altered in CML cells, patient samples from the chronic phase, accelerated phase or blast crisis (myeloid or lymphoid) were assessed by RNase protection analysis, where RNA was available.
Comparison was made with TGF-␤ RII expression in RNA isolated from the peripheral blood leukocytes of normal donors. Characteristics of the samples are outlined in Table 1 . In the majority of these patients, no change in receptor expression with progression of the disease was detected (Figure 2) . One patient showed increased receptor expression in myeloid blast crisis when compared to chronic phase. In all samples analyzed from patients with CML, receptor transcripts were considerably less abundant than in cells from normal donors.
To eliminate the possibility that decreased TGF-␤ RII expression merely reflected the different populations of cells present in the samples, a comparison was made between receptor expression in RNA isolated from purified neutrophils of normal donors and CML patients. RNase protection analysis showed very similar levels of TGF-␤ RII expression in RNA isolated from neutrophils of normal donors, but decreased expression in RNA isolated from neutrophils of CML patients (Figure 3a) .
A decrease in receptor expression in mononuclear populations from patients with CML compared with normal donors was also seen (data not shown). However, populations being Expression of TGF-␤ RII in normal and leukemic hematopoietic cells. RNase protection analysis was performed on total RNA (15 g) isolated from normal donors (N) and patients with CML (P). Samples from the chronic phase (CP), acclerated phase (AP) and blast crisis (BC) of the disease were compared. Markers, controls and probes were as for Figure 1 . compared were not homogeneous as the mononuclear cells of the leukemic patients were dominated by myelocytes.
To establish if the observed downregulation of TGF-␤ RII transcripts was also present in other myeloproliferative disorders, receptor expression was analyzed in neutrophils isolated from patients with PRV or ET. RNase protection analysis, taking into account ␤-actin as a control for RNA loading, demonstrated decreased transcript levels in both these disorders compared with the expression in a normal donor previously shown to be representative (Figure 3b ). In particular, in one ET sample TGF-␤ RII transcripts were almost undetectable. These observations were confirmed by comparing ratios of intensity for each band representing the TGF-␤ RII transcripts to that for each ␤-actin band, as established by scanning densitometry.
Analysis of microsatellite regions in the TGF-␤ type II receptor
The adenine repeat microsatellite found altered in colon cancers was analyzed for deletion or addition of an adenine residue to establish if this region was altered either in the chronic phase of CML or during progression from the chronic to acute phase.
A positive control for analysis of the mutation was confirmed by cycle sequencing a 352 bp PCR product amplified from genomic DNA of the HCT116 colon carcinoma cell line, that included the adenine repeat microsatellite. As previously reported, the HCT116 cell line contains a single adenine deletion, (A) 9 , in this microsatellite. 18 The sequence of Jurkat in the adenine repeat microsatellite region was normal (A) 10 , and therefore provided a negative control. Cycle sequencing of the PCR amplification product initially proved difficult as a second sequence with an adenine deletion was often apparent, suggesting a mutation in one allele. This has been observed by others and attributed to Taq polymerase 'slipping' in the synthesis of the adenine repeat sequence. Optimization of the sequencing reaction minimized this artifact. A minor PCR product of 72 bp that resulted from the same phenomenon was also apparent in the microsatellite analysis outlined below, as previously reported. 20 To investigate the adenine microsatellite region, a 73 bp fragment spanning the region was amplified from genomic DNA samples, with one primer radioactively labelled. PCR products were separated on a polyacrylamide gel and visualised by autoradiography. Inclusion of the positive control (amplified from HCT116 genomic DNA) and negative control (amplified from Jurkat genomic DNA), demonstrated a clear distinction between the (A) 10 and (A) 9 sequence. To simulate a population in which one allele is altered, both HCT116 and Jurkat genomic DNA were included equally as template in the PCR amplification reaction.
Hematopoietic samples are not homogeneous for leukemic cells, thus a heterozygous mutation in the leukemic clone may result in the altered allele being present at a frequency of less than 50%. The sensitivity of the assay was tested by adding HCT116 template in an increasing ratio to Jurkat template. Increased intensity of the 72 bp product as compared with the 73 bp product could be detected where the (A) 9 template was included as 33% of the sample (ratio (A) 10 : (A) 9 of 2:1) (Figure 4a) .
The 73 bp fragment was amplified from leukemic cell lines and primary samples from patients with CML. Analysis of the (A) 10 region in the leukemic cell lines K562 and HL-60 demonstrated no mutation (Figure 4b ). The (A) 10 region from 16 patients with CML was also investigated, where possible comparing chronic phase, accelerated phase and blast crisis samples. No alteration was detected in the microsatellite during the course of the disease (Figure 4c ).
Figure 4
Analysis of a microsatellite region of TGF-␤ RII. A region of the TGF-␤ RII gene encompassing the 10 adenine repeat was amplified by PCR from genomic DNA (100 ng) using one 33 P-end-labelled primer. Products amplified from Jurkat (J) and HCT116 (H) genomic DNAs were included as controls for the absence and presence of the (A) 9 deletion. A heterozygous population was simulated by including both templates equally (J/H). The markers were pBR322 DNA digested with MspI. (a) Sensitivity of the microsatellite assay. Genomic DNA from the human tumor cell lines Jurkat, (A) 10 and HCT116 (A) 9 , were combined at a range of ratios in the template. Where RNA was available (patients 1-5, 15-18), a 262 bp RT-PCR product including the (GT) 3 sequence was directly sequenced. No abnormalities in this region were detected (data not shown). No product could be amplified from this region in K562 and HL-60, supporting RNase protection analysis results that demonstrated no detectable TGF-␤ RII mRNA expression in these cell lines.
Discussion
This study was undertaken to determine if decreased TGF-␤ RII gene expression may play a role in the evolution of CML and whether the short repeat regions in the TGF-␤ RII gene might be targets of the microsatellite instability phenotype previously documented.
Studies of receptor expression by RNase protection analysis demonstrated that the cell lines K562 and HL-60 lack detectable levels of the TGF-␤ RII transcript. The absence of TGF-␤ RII was consistent with the lack of a RT-PCR amplification product in a sensitive PCR reaction. Southern blot analysis of DNA from these cell lines suggested that major abnormalities in the TGF-␤ RII gene were not responsible for the absence of mRNA transcripts. No alteration in the (A) 10 microsatellite region was detected in these cell lines. K562 cells have been reported to differentiate when treated with TGF-␤, suggesting that functional receptor expression can be upregulated. 26 It is thus probable that decreased receptor expression is a result of modulation of transcription or transcript stability rather than mutation of the receptor gene.
Receptor transcripts in cells from CML patients in the chronic, accelerated and acute phases were considerably less abundant than in the peripheral blood cells of normal donors. TGF-␤ RII expression in RNA from purified neutrophil populations also showed decreased expression compared with the same cell population in normal donors. The decrease in receptor expression in neutrophils of CML patients does suggest that the former observation does not merely reflect differences in the cell types isolated from the samples. TGF-␤ RII expression is also decreased in neutrophil populations of cells from patients with PRV and ET. This suggests that decreased expression of TGF-␤ RII may be a more general phenomenon in myeloproliferative disorders.
In hematopoietic progenitor cells, a tight balance must be maintained between positive and negative growth regulation. Downregulation of the TGF-␤ RII in CML cells may enable progenitor cells to bypass the regulatory effects of TGF-␤ required for normal hematopoiesis. With the loss of a negative regulator, the affects of mitogenic signalling pathways such as the Ras pathway, thought to be constitutively active in CML cells, would be further enhanced. TGF-␤ RII expression may be modulated by other signalling pathways, as has been demonstrated in endothelial cells where bFGF downregulates TGF-␤ RII expression and in an esophageal epithelial cell line where overexpression of cyclin D reduces TGF-␤ RII expression. 27, 28 Modulation of TGF-␤ RII expression by growth factor signalling pathways activated by Bcr-Abl may be one explanation for reduced receptor levels in CML cells.
In this study, TGF-␤ RII transcripts were readily detectable in the HCT116 colon carcinoma cell line. This contrasts with the loss of receptor expression documented previously. 18 The disparity in results may reflect the probe design. The probe used here was protected by a region of the TGF-␤ RII transcript encoding part of the kinase domain, not encompassing microsatellite regions or other known sites of mutation. This probe detects transcripts containing the (A) 10 to (A) 9 mutation and should accurately reflect receptor expression in the HCT116 cells cultured. An alternative explanation is that additional mutations may have been acquired in HCT116 subclones during passage of the cells, resulting in the downregulation of receptor expression observed by others.
Inactivation of the TGF-␤ RII by microsatellite alteration appears to be an important mechanism by which some cancer cells displaying the microsatellite instability phenotype can escape the negative regulatory action of TGF-␤. No alteration in the (A) 10 repeat region was detected in the chronic phase of CML or during disease progression. The absence of microsatellite alterations in TGF-␤ RII in the CML cells analyzed in these studies suggests that receptor inactivation by this mechanism is not involved in the progression of CML.
Contradictory reports exist in the literature as to whether microsatellite instability is indeed involved in the evolution of CML. An initial report that over 50% of CMLs developed microsatellite instability during progression from chronic phase to blast crisis 17 was disputed by another study which demonstrated that of 48 CMLs analyzed, none had developed microsatellite instability following transformation to blast crisis. 29 A further study established a lack of microsatellite instability in the progression of 17 CML patients. 30 These differences may, in part, be explained by the technical difficulties associated with detection of microsatellite errors scattered throughout the genome. We hypothesized that if the TGF-␤ RII was a target gene of the RER + phenotype in hematopoietic cells, it could serve as an accurate marker for this phenotype. However, although TGF-␤ is an important negative growth regulator of hematopoietic cells, the absence of errors in the microsatellite region in TGF-␤ RII in blast phase cells neither supports nor disputes the argument that development of microstellite instability is involved in CML progression, as not all RER + tumors contain the TGF-␤ RII microsatellite mutation. For example, the adenine repeat region was found unaltered in endometrial cancers with microsatellite instability, perhaps because other factors supercede TGF-␤ as the dominant negative regulator of endometrial epithelium or alternatively, the cells may escape TGF-␤ growth inhibition by another mechanism. 20 The (A) 10 region of TGF-␤ RII in a subset of chronic lymphocytic leukemias (CLL) which display microsatellite instability is unaltered. 31 Thus, if microsatellite instability does play a role in the progression of CML, it is likely that targets other than TGF-␤ RII are involved.
Microsatellite instability, as determined by stability of repeat regions throughout the genome, has not been consistently shown in hematopoietic disorders. Mutational analysis of the DNA repair enzyme MSH2 in human hematopoietic malignancies demonstrated that 25% of acute myeloid leukemias and 50% of T cell lymphoblastic lymphomas analyzed contained germline mutations in exon 13 of the MSH2 gene. 15 In contrast, mutations were not detected in the B cell acute lymphoblastic leukemias investigated. Expression of human MSH-3, which like MSH-2, exhibits homology to the bacterial MutS mismatch repair protein, is reduced in a number of hematological malignancies.
14 Of CMLs investigated in this study, 90% displayed low or complete loss of MSH-3 expression. Furthermore, mutations in the gene encoding MLH-1, another component of the mismatch repair complex, have been observed in cell lines established from lymphoid leukemias. 16 The importance of DNA repair to the integrity of the hematopoietic system is further illustrated by mice with a targeted disruption of the MSH-2 gene. 13 These mice have an increased susceptibility to lymphoblastic lymphomas, which closely resemble human precursor T cell lymphomas at a histologic and molecular level. 32 The homogeneous nature of the murine tumors suggests that the microsatellite instability results in specific, recurring activating events. However, although microsatellite instability and alteration of the TGF-␤ RII have been detected in ALL cell lines, no evidence for this has been found in vivo. 33 Interestingly, loss of TGF-␤ RII expression has been associated with the progression of cutaneous T cell lymphomas and Sézary syndrome. 34, 35 Intracellular components of the TGF-␤ signalling pathway may prove to be important in leukemogenesis. CLL cells display resistance to the apoptotic affects of TGF-␤, despite a normal growth inhibition response, suggesting that while the receptor is unaltered, downstream mediators of the TGF-␤ signal are perturbed. 36 A family of proteins, the Smads, related to Mad, a D. melanogaster gene, and the Sma genes of C. elegans, are downstream mediators of TGF-␤ superfamily members (reviewed in Ref. 37 ). Smad2 and/or Smad3 in concert with Smad4 act downstream of TGF-␤. The importance of the Smad proteins in growth regulation is underscored by the finding of mutations in these genes in human malignancies. Smad4 was identified as a candidate tumour suppressor, deleted in pancreatic cancers. 38 Mutations of Smad2 have been detected in colorectal cancers. 39 The results of this study suggest that inactivation of TGF-␤ RII by microsatellite alteration is not a mechanism which CML cells employ to escape TGF-␤ negative growth regulation. However, receptor transcripts are absent in K562, a cell line derived from a patient in CML blast crisis and downregulated in cells from both the chronic and acute phases of CML. While the level of TGF-␤ RII expression does not alter with disease progression in the majority of cases, the possibility is raised that decreased expression of TGF-␤ RII may play a permissive role in the evolution of CML. A similar decrease in receptor transcripts in ET and PRV suggests that downregulation of TGF-␤ RII may be a mechanism which facilitates clonal expansion of an abnormal stem cell.
